254 related articles for article (PubMed ID: 23369087)
21. Production, characterization and applications of a tetanus toxin specific monoclonal antibody T-62.
Petrušić V; Zivković I; Stojanović M; Stojićević I; Marinković E; Dimitrijević L
Acta Histochem; 2012 Sep; 114(5):480-6. PubMed ID: 21975055
[TBL] [Abstract][Full Text] [Related]
22. Co-expression of tetanus toxin fragment C in Escherichia coli with thioredoxin and its evaluation as an effective subunit vaccine candidate.
Yu YZ; Gong ZW; Ma Y; Zhang SM; Zhu HQ; Wang WB; Du Y; Wang S; Yu WY; Sun ZW
Vaccine; 2011 Aug; 29(35):5978-85. PubMed ID: 21718736
[TBL] [Abstract][Full Text] [Related]
23. Expression of tetanus toxin subfragments in vitro and characterization of epitopes.
Andersen-Beckh B; Binz T; Kurazono H; Mayer T; Eisel U; Niemann H
Infect Immun; 1989 Nov; 57(11):3498-505. PubMed ID: 2478475
[TBL] [Abstract][Full Text] [Related]
24. Production and characterization of monoclonal antibodies against vaginolysin: mapping of a region critical for its cytolytic activity.
Zvirbliene A; Pleckaityte M; Lasickiene R; Kucinskaite-Kodze I; Zvirblis G
Toxicon; 2010 Aug; 56(1):19-28. PubMed ID: 20298711
[TBL] [Abstract][Full Text] [Related]
25. Passive vaccination with a human monoclonal antibody: generation of antibodies and studies for efficacy in Bacillus anthracis infections.
vor dem Esche U; Huber M; Zgaga-Griesz A; Grunow R; Beyer W; Hahn U; Bessler WG
Immunobiology; 2011 Jul; 216(7):847-53. PubMed ID: 21397977
[TBL] [Abstract][Full Text] [Related]
26. Isolation and characterization of a novel human monoclonal antibody that neutralizes tetanus toxin.
Simpson LL; Lake P; Kozaki S
J Pharmacol Exp Ther; 1990 Jul; 254(1):98-103. PubMed ID: 1694896
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of toxin-neutralization by anti-tetanus human monoclonal antibodies directed against the three functional domains [A], [B] and [C] of the tetanus toxin molecule and a reliable method for evaluating the protective effects of monoclonal antibodies.
Matsuda M; Kamei M; Sugimoto N; Ma Y; Hashizume S
Eur J Epidemiol; 1992 Jan; 8(1):1-8. PubMed ID: 1572415
[TBL] [Abstract][Full Text] [Related]
28. Characterization of neutralizing chimeric heavy-chain antibodies against tetanus toxin.
Cheng K; Lu J; Guo J; Wang R; Chen L; Wang X; Jiang Y; Li Y; Xu C; Kang Q; Qiaerxie G; Du P; Gao C; Yu Y; Yang Z; Wang W
Hum Vaccin Immunother; 2024 Dec; 20(1):2366641. PubMed ID: 38934499
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms.
Zhao H; Nakamura K; Kohda T; Mukamoto M; Kozaki S
Jpn J Infect Dis; 2012; 65(2):138-45. PubMed ID: 22446121
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy with human monoclonal antibodies. Fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin.
Lang AB; Cryz SJ; Schürch U; Ganss MT; Bruderer U
J Immunol; 1993 Jul; 151(1):466-72. PubMed ID: 8326138
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibodies as probes of tetanus toxin structure and function.
Kenimer JG; Habig WH; Hardegree MC
Infect Immun; 1983 Dec; 42(3):942-8. PubMed ID: 6642671
[TBL] [Abstract][Full Text] [Related]
32. Epitope Mapping of Tetanus Toxin by Monoclonal Antibodies: Implication for Immunotherapy and Vaccine Design.
Ghotloo S; Golsaz-Shirazi F; Amiri MM; Jeddi-Tehrani M; Shokri F
Neurotox Res; 2020 Feb; 37(2):239-249. PubMed ID: 31410686
[TBL] [Abstract][Full Text] [Related]
33. An immunodominant epitope in a functional domain near the N-terminus of human granulocyte-macrophage colony-stimulating factor identified by cross-reaction of synthetic peptides with neutralizing anti-protein and anti-peptide antibodies.
Beffy P; Rovero P; Di Bartolo V; Laricchia Robbio L; Dané A; Pegoraro S; Bertolero F; Revoltella RP
Hybridoma; 1994 Dec; 13(6):457-68. PubMed ID: 7737670
[TBL] [Abstract][Full Text] [Related]
34. Reduction of the ganglioside binding activity of the tetanus toxin HC fragment destroys immunogenicity: implications for development of novel tetanus vaccines.
Qazi O; Sesardic D; Tierney R; Söderbäck Z; Crane D; Bolgiano B; Fairweather N
Infect Immun; 2006 Aug; 74(8):4884-91. PubMed ID: 16861677
[TBL] [Abstract][Full Text] [Related]
35. Neutralizing murine monoclonal antibodies to human IL-5 isolated from hybridomas and a filamentous phage Fab display library.
Ames RS; Tornetta MA; McMillan LJ; Kaiser KF; Holmes SD; Appelbaum E; Cusimano DM; Theisen TW; Gross MS; Jones CS
J Immunol; 1995 Jun; 154(12):6355-64. PubMed ID: 7759873
[TBL] [Abstract][Full Text] [Related]
36. [Preparation, epitope analysis and clinical application of monoclonal antibodies against heart-type fatty acid binding protein].
Han Q; Cong S; Yi W; Chen S; Liang W; Chen A; Hu C; Li S
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jun; 29(6):620-4. PubMed ID: 23746246
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibodies against tetanus toxin and toxoid.
Ahnert-Hilger G; Bizzini B; Goretzki K; Müller H; Völckers C; Habermann E
Med Microbiol Immunol; 1983; 172(2):123-35. PubMed ID: 6193402
[TBL] [Abstract][Full Text] [Related]
38. Monoclonal anti-H1 histone autoantibodies from unimmunized Balb/c mice. Specificity and VH and VL domain sequences.
Underwood JR; Cartwright GA; McCall AM; Tribbick G; Geysen MH; Hearn MT
J Autoimmun; 1994 Jun; 7(3):291-320. PubMed ID: 7916905
[TBL] [Abstract][Full Text] [Related]
39. Contribution of Fc fragment of monoclonal antibodies to tetanus toxin neutralization.
Ghotloo S; Amiri MM; Khoshnoodi J; Abbasi E; Jeddi-Tehrani M; Golsaz-Shirazi F; Shokri F
Neurotox Res; 2020 Mar; 37(3):578-586. PubMed ID: 31721050
[TBL] [Abstract][Full Text] [Related]
40. Tetanus neurotoxin HCC protein commits T cells to IFN-γ producing cells.
Torabi Goudarzi S; Hajivalili M; Hosseini M; Ghafari Khamene M; Yazdani Y; Sadreddini S; Miahipour A; Younesi V; Yousefi M
Cell Mol Biol (Noisy-le-grand); 2016 Mar; 62(3):20-4. PubMed ID: 27064869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
